Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01635023 · ClinicalTrials.gov registry record · Phase 1
A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01635023 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 27 participants.
The verdict
NCT01635023, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
Study in Healthy Males to Compare the White and Blue Formulations of AZD6244.
Interventions
- DRUG AZD6244 Dosing Period 1
- DRUG AZD6244 Dosing Period 2
- DRUG AZD6244 Dosing Period 3
- DRUG AZD6244 Dosing Period 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01635023
The ClinicalTrials.gov registry entry for NCT01635023 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which AZD6244 Dosing Period 1 is the first listed.
NCT01635023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01635023 about?
NCT01635023 is a clinical study titled "A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244". Study in Healthy Males to Compare the White and Blue Formulations of AZD6244.
What is the current status of trial NCT01635023?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2012-07. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01635023?
The interventions under investigation include: AZD6244 Dosing Period 1 (DRUG), AZD6244 Dosing Period 2 (DRUG), AZD6244 Dosing Period 3 (DRUG), AZD6244 Dosing Period 4 (DRUG).
Who is sponsoring clinical trial NCT01635023?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.